Evotec SE

Evotec is a German-listed drug discovery/development contract research organization (CRO) whose stock has been cut in half over the last twelve months. At $1.91, a fresh AI-partnership announcement with Odyssey Therapeutics gives the equity a specific reason to reprice.

• The revenue base is real but earnings-thin: quarterly revenue ran $171M / $164M / $251M / $159M with gross margin around 11%, quarterly EPS at $-0.12 / $-0.12 / $0.04 / $-0.35 — analysts model $601M and $-0.47 EPS for the full year, so this is a services business in a down-cycle margin phase.
• The Odyssey AI collaboration is a real specific catalyst: Evotec and Odyssey Therapeutics entered an AI-enabled R&D collaboration in autoimmune and inflammatory diseases — that's the kind of partnership that opens a new revenue lane at a moment when biotech CROs are being reframed by AI-drug-discovery narratives.
• The customer stack keeps expanding: Niagen Bioscience selecting Evotec to advance preclinical development for NB4168 is a routine but ongoing win that adds a modest revenue increment and reinforces the CRO's positioning in the small-cap-biotech tail.

A Nov 5 print that shows revenue growth stabilizing and adds any commercial commentary on the Odyssey partnership extends the coil into a real recovery toward brokerage $3.00 PTs; another negative gross-margin quarter, a customer-concentration disclosure, or a biotech-CRO industry pricing move is what invalidates the setup.